November 12th 2024
The FDA cleared Novavax to start enrolling the planned phase 3 trial after a safety concern was found to be unrelated to the combination vaccine.
November 11th 2024
Insights on how to manage the "triple threat" of flu, RSV, and COVID-19 this season.
October 7th 2024
Less than one-quarter of people infected with influenza-associated severe acute respiratory illness were vaccinated, according to a new report.
September 30th 2024
Your daily dose of the clinical news you may have missed.
September 20th 2024
FluMist is the first influenza vaccine that does not have to be given by a health care professional.
ID Specialist Underscores Vital Role of Vaccination among Health Care Professionals this Flu Season at IDWeek 2023
Clinicians must remember the point of vaccines was not to prevent infection, but to decrease severity of illness, says infectious disease specialist Gopi Patel, MD.
ID Specialist to Colleagues: Don’t Pass Your Germs to Your Patients This Flu Season
Gopi Patel, MD, emphasizes the importance of promoting vaccination and infection prevention measures among fellow clinicians, as well as patients, this season.
Daily Dose: Meningococcal Vaccination Coverage Disparities in the US
IDWeek 2023: New Research Identifies Disparities in COVID-19 Vaccine Coverage Within a Large, Racially and Ethnically Diverse Population
IDWeek 2023. The study identified disparities in coverage related to age, race, ethnicity, household income, insurance status, and prior influenza vaccination.
IDWeek 2023: Seasonal Flu Vaccine Offers More Protection for Immunocompetent Adults than Immunocompromised Peers, but “Difference not Statistically Significant”
Researchers say findings demonstrate the capacity to use an existing influenza vaccine effectiveness network to study a large immunocompromised population.
Adolescents Prefer Combination Meningococcal Vaccine to Separate MenACWY and MenB Administration a New Study Finds
IDWeek 2023: Adolescents expressed a preference for a combination vaccine covering serogroups A, B, C, W, Y of invasive meningococcal disease, reported researchers.
US Meningococcal Vaccination Coverage Has Increased, but Disparities Persist, According to Data Presented at IDWeek 2023
Findings underscore the persistence of disparities in meningococcal vaccination coverage in the US, particularly for vaccination against serogroup B.
COVID-19 Monovalent Vaccines: An ACIP Recommendations Quiz
A 2-question quiz on the ACIP's recommendations on the new COVID-19 monovalent vaccines that provide protection from currently circulating strains.
Updated Novavax COVID-19 Vaccine Authorized by FDA to Protect Against Current Variants
The Novavax COVID-19 vaccine is refreshed with 2023-2024 formula targeting the XBB.1.5 strain.
ACIP Recommends Maternal RSV Vaccine to Protect Newborns
Members of the ACIP voted on Friday to recommend Pfizer’s maternal bivalent RSVpreF vaccine to protect newborns from severe RSV illness.
Daily Dose: COVID-19 Vaccination Decreases Symptoms of Long COVID
Your daily dose of clinical news you may have missed.
COVID-19 Vaccination May Decrease Symptoms of Long COVID, Report Mayo Clinic Researchers
Vaccination against SARS-CoV-2 may decrease the symptoms of post-COVID conditions, such as abdominal pain and weakness, according to new study.
New-Onset Inflammatory Rheumatic Diseases May be Triggered by SARS-CoV-2 Infection or COVID-19 Vaccines, According to Recent Data
Findings from a recent study show a broad spectrum of possible clinical manifestations of IRD following SARS-CoV-2 infection or COVID-19 vaccination.
Daily Dose: How COVID-19 Vaccination Can Reduce Severity, Mortality after SARS-CoV-2 Infection
A daily dose of clinical news on Patient Care you may have missed.
Daily Dose: Electronic “Nudges” to Increase Flu Vaccination Uptake
Electronic “Nudges” Linking Flu Vaccination to Potential CV Benefits Boosted Uptake in Older Adults in Denmark
ACC 2023. Electronic nudges highlighting the potential cardiovascular benefits of flu vaccination led to a modest uptake in vaccination rates among older adults in Denmark, according to results of the NUDGE-FLU trial.
Immunization Levels Disheartening This Flu Season, Says William Schaffner, MD
Vaccine uptake this respiratory virus season is lagging compared to previous years, says Schaffner, medical director of the National Foundation for Infectious Diseases.
Respiratory Tripledemic 2022-23: Expert Update, Top Challenges
Distinguishing between influenza, COVID-19, and RSV and persuading vaccine-weary patients to get vaccinated are some of the challenges this season, says William Schaffner, MD.
CDC Releases First Estimates of Bivalent mRNA COVID-19 Booster Effectiveness against XBB/XBB.1.5
Preliminary estimates showed relative bivalent booster dose vaccine effectiveness against XBB/XBB.1.5 for at least the first 3 months after vaccination.
ACIP 2023 Vaccination Schedule Update, At-a-Glance
Among the CDC vaccine advisory group's recommendations are adding COVID-19 vaccines to the Vaccine for Children program and allowing PCV20 shots for those who previously received PCV13.
Daily Dose: Bivalent Boosters Protect Against Severe COVID-19 Disease
Daily Dose: Parent-Pediatrician Vaccine Discussions Lagging?
Parent-Pediatrician Vaccine Discussions are Lagging, National Poll Finds
One in 7 parents have not discussed vaccines with their child's primary clinician during the 2-year pandemic period, according to a CS Mott Children's Hospital poll.
Investigational Fentanyl Vaccine Could Block the Opioid from the Brain
A vaccine against fentanyl could stop the intense euphoria the drug creates and also block dangerous physiologic responses like respiratory depression, a new study suggests.
Pediatric RSV Vaccines: Why Are We Still Waiting?
I have admitted infants to the hospital every winter for 40 years, yet I still don't have good answers for anxious parents watching their child struggling to breathe.
Maternal RSV Vaccine Prevents Infection in Infants, Pfizer Announces
Topline phase 3 trial data showed 81.8% efficacy for the maternal vaccine against severe RSV-related illness in infants from birth through first 90 days of life.
Adult RSV Vaxx Gets EMA Nod: Can USA be Far Behind?
The GSK RSV vaccine candidate has received favorable international regulatory attention which may be an auspicious sign for the US.
Daily Dose: Recombinant Zoster Vaccine Provides 10 Years of Protection
Daily Dose: High-dose Flu Vaccine Consistently More Effective vs Standard-dose
Recombinant Zoster Vaccine Protection Durable at 10 Years, New Study Finds
Efficacy of the RZV vaccine against herpes zoster infection remained >80% in a long-term follow-up study representing 10 years since initial immunization.